CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Recruiting · NCT06031727 · Registry updated 2025-03-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) | Neovascular Age-related Macular Degeneration(nAMD) | Recruiting | Early phase 1 | 2025-03-17 | NCT06031727 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eye & ENT Hospital of Fudan University | 64 |
| HuidaGene Therapeutics Co., Ltd. | 6 |
| Tianjin Medical University Eye Hospital | 16 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Eye & Ent Hospital of Fudan University | Shanghai | China | 6 |
| Tianjin Medical University Eye Hospital | Tianjin | China | 1 |